Danh mục

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

Số trang: 8      Loại file: pdf      Dung lượng: 731.14 KB      Lượt xem: 4      Lượt tải: 0    
10.10.2023

Xem trước 2 trang đầu tiên của tài liệu này:

Thông tin tài liệu:

Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tolerated dose, and recommended phase II dose and schedule of oral ridaforolimus combined with paclitaxel and carboplatin in patients with solid tumor cancers.
Nội dung trích xuất từ tài liệu:
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

Tài liệu được xem nhiều: